Sarepta Therapeutics Inc Financials
Sarepta Therapeutics Inc (SRPT) reported $2.2B in revenue for fiscal year 2025, up 15.6% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue is expanding, but research intensity and working-capital absorption still keep Sarepta from becoming a self-funding business.
The most revealing pattern is that FY2024's profit did not mark a cash inflection: net income turned positive at$235M , yet operating cash flow remained negative at-$206M , so the apparent earnings breakthrough was still being absorbed inside operations. In FY2025, revenue still climbed to$2.2B while the company posted a-$713M loss, which points to deliberately heavier reinvestment rather than a simple demand collapse or commercial unwind.
The 2025 earnings reversal was driven more by expense mix than by sales weakness. Revenue rose from
The working-capital posture has grown heavier, so reported progress is still consuming cash inside the business rather than releasing it; that is a day-to-day funding issue more than a leverage issue. The current ratio fell from 4.2x to 2.3x even though debt did not rise, which points to liquidity pressure from operations rather than a balance sheet newly loaded with borrowings.
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Sarepta Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Sarepta Therapeutics Inc has an operating margin of -31.8%, meaning the company loses $32 on every $100 of revenue. This results in a profitability score of 24/100. This is down from 11.5% the prior year.
Sarepta Therapeutics Inc's revenue surged 15.6% year-over-year to $2.2B, reflecting rapid business expansion. This strong growth earns a score of 90/100.
Sarepta Therapeutics Inc has a moderate D/E ratio of 0.73. This balance of debt and equity financing earns a leverage score of 52/100.
With a current ratio of 2.32, Sarepta Therapeutics Inc holds $2.32 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 65/100.
Sarepta Therapeutics Inc's operations used $205.5M of cash, and capex of $102.0M added to the outflow, for a free cash flow shortfall of $307.5M. This results in a cash flow score of 12/100.
Sarepta Therapeutics Inc posts a -62.5% return on equity (ROE), meaning it loses $63 for every $100 of shareholders' equity. This results in a returns score of 23/100. This is down from 15.4% the prior year.
Sarepta Therapeutics Inc scores -1.04, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($1.9B) relative to total liabilities ($2.2B). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Sarepta Therapeutics Inc passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
Sarepta Therapeutics Inc reported a net loss of $713.4M while operations used $205.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Sarepta Therapeutics Inc reported an operating loss of $699.8M against $38.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Sarepta Therapeutics Inc generated $2.2B in revenue in fiscal year 2025. This represents an increase of 15.6% from the prior year.
Sarepta Therapeutics Inc's EBITDA was -$655.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 356.2% from the prior year.
Sarepta Therapeutics Inc reported -$713.4M in net income in fiscal year 2025. This represents a decrease of 403.3% from the prior year.
Sarepta Therapeutics Inc earned -$7.13 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 404.7% from the prior year.
Cash & Balance Sheet
Sarepta Therapeutics Inc recorded an outflow of $307.5M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 10.3% from the prior year.
Sarepta Therapeutics Inc held $801.3M in cash against $829.0M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Sarepta Therapeutics Inc's gross margin was 98.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs.
Sarepta Therapeutics Inc's operating margin was -31.8% in fiscal year 2025, reflecting core business profitability. This is down 43.3 percentage points from the prior year.
Sarepta Therapeutics Inc's net profit margin was -32.5% in fiscal year 2025, showing the share of revenue converted to profit. This is down 44.8 percentage points from the prior year.
Sarepta Therapeutics Inc's ROE was -62.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 78.0 percentage points from the prior year.
Capital Allocation
Sarepta Therapeutics Inc invested $1.5B in research and development in fiscal year 2025. This represents an increase of 89.2% from the prior year.
Sarepta Therapeutics Inc spent $25.0M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.
Sarepta Therapeutics Inc invested $102.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 25.5% from the prior year.
SRPT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.0B | $2.2B+15.6% | $1.9B+53.0% | $1.2B+33.3% | $933.0M+32.9% | $701.9M+30.0% | $540.1M+41.8% | $380.8M+26.5% | $301.0M+94.7% | $154.6M+2751.6% | $5.4M+332.6% | $1.3M-87.2% | $9.8M | N/A | N/A | N/A |
| Cost of Revenue | N/A | $25.5M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $130K | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $2.2B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $5.3M | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $1.5B+89.2% | $804.5M-8.3% | $877.4M0.0% | $877.1M+13.7% | $771.2M+6.8% | $722.3M+28.8% | $560.9M+39.6% | $401.8M+141.0% | $166.7M-11.5% | $188.3M+28.6% | $146.4M+55.4% | $94.2M+29.2% | $72.9M+39.1% | $52.4M-21.6% | $66.9M |
| SG&A Expenses | N/A | $491.7M-11.9% | $557.9M+15.8% | $481.9M+6.7% | $451.4M+59.7% | $282.7M-11.1% | $317.9M+11.6% | $284.8M+37.1% | $207.8M+69.3% | $122.7M+46.5% | $83.7M+11.6% | $75.0M+52.2% | $49.3M+56.1% | $31.6M+116.0% | $14.6M-8.9% | $16.1M |
| Operating Income | N/A | -$699.8M-420.9% | $218.1M+181.4% | -$267.8M+50.1% | -$536.2M-16.6% | -$459.7M+18.5% | -$564.2M+20.0% | -$705.6M-105.3% | -$343.6M-100.2% | -$171.6M+35.7% | -$266.7M-21.1% | -$220.2M-64.6% | -$133.8M-48.2% | -$90.3M-204.0% | -$29.7M+17.3% | -$35.9M |
| Interest Expense | N/A | -$38.1M-107.4% | -$18.4M+16.4% | -$22.0M+58.7% | -$53.2M-183.8% | $63.5M+6.0% | $59.9M+95.5% | $30.7M-9.0% | $33.7M+481.1% | $5.8M+206.6% | $1.9M+38.6% | $1.4M+1265.0% | $100K0.0% | $100K0.0% | $100K0.0% | $100K |
| Income Tax | N/A | $11.2M-56.2% | $25.5M+60.8% | $15.9M+17.4% | $13.5M+8150.6% | -$168K-115.8% | $1.1M-11.0% | $1.2M+272.7% | -$692K-133.6% | $2.1M | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$136.7M | -$713.4M-403.3% | $235.2M+143.9% | -$536.0M+23.8% | -$703.5M-68.0% | -$418.8M+24.4% | -$554.1M+22.5% | -$715.1M-97.6% | -$361.9M-614.0% | -$50.7M+81.0% | -$267.3M-21.5% | -$220.0M-62.0% | -$135.8M-21.3% | -$112.0M+7.7% | -$121.3M-5132.4% | -$2.3M |
| EPS (Diluted) | -$1.60 | -$7.13-404.7% | $2.34+140.3% | -$5.80+27.8% | -$8.03-55.9% | -$5.15+27.6% | -$7.11 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -$0.02 |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
SRPT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $3.3B-15.5% | $4.0B+21.4% | $3.3B+4.4% | $3.1B-0.6% | $3.1B+5.5% | $3.0B+63.7% | $1.8B+11.0% | $1.6B+25.5% | $1.3B+208.4% | $424.1M+54.9% | $273.8M-7.2% | $295.0M+1.2% | $291.6M+42.2% | $205.0M+277.0% | $54.4M |
| Current Assets | $2.5B-17.4% | $3.1B+19.2% | $2.6B+0.8% | $2.6B-1.8% | $2.6B+4.8% | $2.5B+69.2% | $1.5B+3.0% | $1.4B+16.1% | $1.2B+229.0% | $373.5M+66.3% | $224.5M-9.4% | $247.8M-8.5% | $270.8M+39.7% | $193.9M+329.2% | $45.2M |
| Cash & Equivalents | $801.3M-27.4% | $1.1B+157.5% | $428.4M-55.7% | $966.8M-54.3% | $2.1B+40.8% | $1.5B+79.9% | $835.1M+125.2% | $370.8M-38.2% | $599.7M+389.9% | $122.4M+52.4% | $80.3M+9.2% | $73.6M-71.4% | $257.0M+36.9% | $187.7M+370.3% | $39.9M |
| Inventory | $914.7M+22.0% | $750.0M+132.3% | $322.9M+58.3% | $204.0M+9.5% | $186.2M-19.7% | $232.0M+35.3% | $171.4M+36.6% | $125.4M+50.0% | $83.6M+552.5% | $12.8M | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $398.2M-33.8% | $602.0M+50.4% | $400.3M+86.5% | $214.6M+40.3% | $153.0M+51.0% | $101.3M+11.5% | $90.9M+85.3% | $49.0M+66.4% | $29.5M+463.7% | $5.2M+31.5% | $4.0M+64.6% | $2.4M-31.6% | $3.5M-25.1% | $4.7M+29.7% | $3.6M |
| Total Liabilities | $2.2B-9.3% | $2.4B+1.3% | $2.4B-12.3% | $2.7B+23.6% | $2.2B-0.1% | $2.2B+121.3% | $1.0B+64.7% | $609.8M+17.6% | $518.7M+493.4% | $87.4M+4.8% | $83.4M+76.1% | $47.4M+6.8% | $44.4M-45.4% | $81.3M+248.2% | $23.4M |
| Current Liabilities | $1.1B+49.7% | $731.7M+11.9% | $653.7M+5.5% | $619.6M+36.9% | $452.7M+8.8% | $416.0M+57.1% | $264.8M+52.4% | $173.7M+96.6% | $88.3M+17.1% | $75.4M+21.1% | $62.3M+69.0% | $36.9M+2.5% | $36.0M-54.4% | $78.9M+282.9% | $20.6M |
| Long-Term Debt | $829.0M-27.1% | $1.1B-8.1% | $1.2B-19.8% | $1.5B+174.0% | $563.7M | N/A | N/A | $420.6M-2.4% | $431.1M+2339.7% | $17.7M-34.2% | $26.8M+1718.3% | $1.5M-6.3% | $1.6M-5.5% | $1.7M-5.1% | $1.8M |
| Total Equity | $1.1B-25.3% | $1.5B+77.8% | $859.3M+123.2% | $384.9M-58.5% | $928.0M+21.8% | $761.8M-6.9% | $818.2M-20.7% | $1.0B+30.8% | $789.2M+134.4% | $336.7M+76.9% | $190.3M-23.1% | $247.7M+0.2% | $247.2M+99.9% | $123.7M+298.7% | $31.0M |
| Retained Earnings | -$4.9B-15.8% | -$4.2B+5.3% | -$4.4B-13.7% | -$3.9B-21.9% | -$3.2B-12.6% | -$2.8B-24.2% | -$2.3B-45.3% | -$1.6B-29.7% | -$1.2B-4.3% | -$1.2B-29.7% | -$899.1M-32.4% | -$679.0M-25.0% | -$543.2M | N/A | N/A |
Not reported in any period shown, so not listed: Goodwill.
SRPT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $111.0M | -$205.5M+0.1% | -$205.8M+58.9% | -$501.0M-54.0% | -$325.3M+26.6% | -$443.2M-512.4% | $107.5M+123.5% | -$456.5M-17.4% | -$388.7M-67.5% | -$232.0M+5.6% | -$245.8M-64.5% | -$149.5M-16.3% | -$128.5M-98.7% | -$64.7M-117.9% | -$29.7M-25.4% | -$23.7M |
| Capital Expenditures | $29.2M | $102.0M-25.5% | $137.0M+80.0% | $76.1M+146.9% | $30.8M-19.9% | $38.5M-53.2% | $82.2M+37.9% | $59.6M-2.5% | $61.2M+409.6% | $12.0M+124.7% | $5.3M+57.0% | $3.4M-86.6% | $25.4M+973.6% | $2.4M+2094.4% | $108K-90.8% | $1.2M |
| Free Cash Flow | $81.8M | -$307.5M+10.3% | -$342.7M+40.6% | -$577.1M-62.0% | -$356.2M+26.1% | -$481.7M-2006.5% | $25.3M+104.9% | -$516.1M-14.7% | -$449.8M-84.4% | -$244.0M+2.9% | -$251.2M-64.3% | -$152.9M+0.7% | -$154.0M-129.6% | -$67.1M-125.0% | -$29.8M-19.9% | -$24.9M |
| Investing Cash Flow | $100.8M | $69.6M-90.8% | $755.6M+555.7% | -$165.8M+84.2% | -$1.0B-311.3% | $495.4M+507.0% | -$121.7M-142.5% | $286.7M+177.4% | -$370.5M-107.2% | -$178.8M-98.3% | -$90.2M | N/A | N/A | -$11.7M-919.4% | -$1.1M+50.3% | -$2.3M |
| Financing Cash Flow | -$156.8M | -$168.3M-234.9% | $124.8M-0.2% | $125.0M-46.2% | $232.5M-58.6% | $561.6M-17.7% | $682.3M+6.2% | $642.6M+21.2% | $530.1M-40.3% | $888.1M+134.9% | $378.1M | N/A | N/A | $145.7M-18.4% | $178.6M+452.9% | $32.3M |
| Share Buybacks | N/A | $25.0M | $0 | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
SRPT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 98.8% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 97.6% | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -31.8%-43.3pp | 11.5%+33.0pp | -21.5%+35.9pp | -57.5%+8.0pp | -65.5% | -104.5% | -185.3% | -114.1% | -111.0% | -4920.3% | -17572.6% | -1371.2% | N/A | N/A | N/A |
| Net Margin | -32.5%-44.8pp | 12.4%+55.5pp | -43.1%+32.3pp | -75.4%-15.7pp | -59.7% | -102.6% | -187.8% | -120.2% | -32.8% | -4930.2% | -17560.3% | -1391.7% | N/A | N/A | N/A |
| Return on Equity | -62.5%-78.0pp | 15.4%+77.8pp | -62.4%+120.4pp | -182.8%-137.6pp | -45.1%+27.6pp | -72.7%+14.7pp | -87.4%-52.3pp | -35.1%-28.6pp | -6.4%+73.0pp | -79.4%+36.2pp | -115.6%-60.8pp | -54.8%-9.5pp | -45.3%+52.8pp | -98.1%-90.6pp | -7.5% |
| Return on Assets | -21.3%-27.2pp | 5.9%+22.4pp | -16.4%+6.1pp | -22.5%-9.2pp | -13.3%+5.3pp | -18.6%+20.7pp | -39.2%-17.2pp | -22.0%-18.2pp | -3.9%+59.1pp | -63.0%+17.3pp | -80.4%-34.3pp | -46.0%-7.6pp | -38.4%+20.8pp | -59.2%-54.9pp | -4.3% |
| Current Ratio | 2.32-1.9x | 4.20+0.3x | 3.95-0.2x | 4.13-1.6x | 5.75-0.2x | 5.97+0.4x | 5.55-2.7x | 8.21-5.7x | 13.91+9.0x | 4.95+1.3x | 3.60-3.1x | 6.72-0.8x | 7.53+5.1x | 2.46+0.3x | 2.19 |
| Debt-to-Equity | 0.730.0x | 0.74-0.7x | 1.44-2.6x | 4.01+3.4x | 0.61-2.3x | 2.92+1.7x | 1.23+0.8x | 0.41-0.1x | 0.55+0.5x | 0.05-0.1x | 0.14+0.1x | 0.010.0x | 0.010.0x | 0.010.0x | 0.06 |
| FCF Margin | -14.0%+4.0pp | -18.0%+28.4pp | -46.4%-8.3pp | -38.2%+30.5pp | -68.6%-73.3pp | 4.7% | -135.5% | -149.4% | -157.8% | -4633.1% | -12200.0% | -1578.2% | N/A | N/A | N/A |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Sarepta Therapeutics Inc Ranks
Frequently Asked Questions
What is Sarepta Therapeutics Inc's annual revenue?
Sarepta Therapeutics Inc (SRPT) reported $2.2B in total revenue for fiscal year 2025. This represents a 15.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Sarepta Therapeutics Inc's revenue growing?
Sarepta Therapeutics Inc (SRPT) revenue grew by 15.6% year-over-year, from $1.9B to $2.2B in fiscal year 2025.
Is Sarepta Therapeutics Inc profitable?
No, Sarepta Therapeutics Inc (SRPT) reported a net income of -$713.4M in fiscal year 2025, with a net profit margin of -32.5%.
What is Sarepta Therapeutics Inc's EBITDA?
Sarepta Therapeutics Inc (SRPT) had EBITDA of -$655.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Sarepta Therapeutics Inc have?
As of fiscal year 2025, Sarepta Therapeutics Inc (SRPT) had $801.3M in cash and equivalents against $829.0M in long-term debt.
What is Sarepta Therapeutics Inc's gross margin?
Sarepta Therapeutics Inc (SRPT) had a gross margin of 98.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Sarepta Therapeutics Inc's operating margin?
Sarepta Therapeutics Inc (SRPT) had an operating margin of -31.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Sarepta Therapeutics Inc's net profit margin?
Sarepta Therapeutics Inc (SRPT) had a net profit margin of -32.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Sarepta Therapeutics Inc's return on equity (ROE)?
Sarepta Therapeutics Inc (SRPT) has a return on equity of -62.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Sarepta Therapeutics Inc's free cash flow?
Sarepta Therapeutics Inc (SRPT) recorded an outflow of $307.5M in free cash flow during fiscal year 2025. This represents a 10.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Sarepta Therapeutics Inc's operating cash flow?
Sarepta Therapeutics Inc (SRPT) recorded an outflow of $205.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Sarepta Therapeutics Inc's total assets?
Sarepta Therapeutics Inc (SRPT) had $3.3B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Sarepta Therapeutics Inc's capital expenditures?
Sarepta Therapeutics Inc (SRPT) invested $102.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Sarepta Therapeutics Inc spend on research and development?
Sarepta Therapeutics Inc (SRPT) invested $1.5B in research and development during fiscal year 2025.
What is Sarepta Therapeutics Inc's current ratio?
Sarepta Therapeutics Inc (SRPT) had a current ratio of 2.32 as of fiscal year 2025, which is generally considered healthy.
What is Sarepta Therapeutics Inc's debt-to-equity ratio?
Sarepta Therapeutics Inc (SRPT) had a debt-to-equity ratio of 0.73 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Sarepta Therapeutics Inc's return on assets (ROA)?
Sarepta Therapeutics Inc (SRPT) had a return on assets of -21.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Sarepta Therapeutics Inc's cash runway?
Based on fiscal year 2025 data, Sarepta Therapeutics Inc (SRPT) had $801.3M in cash against an annual operating cash burn of $205.5M. This gives an estimated cash runway of approximately 47 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Sarepta Therapeutics Inc's Altman Z-Score?
Sarepta Therapeutics Inc (SRPT) has an Altman Z-Score of -1.04, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Sarepta Therapeutics Inc's Piotroski F-Score?
Sarepta Therapeutics Inc (SRPT) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Sarepta Therapeutics Inc's earnings high quality?
Sarepta Therapeutics Inc (SRPT) reported a net loss of $713.4M while operations used $205.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Sarepta Therapeutics Inc cover its interest payments?
Sarepta Therapeutics Inc (SRPT) reported an operating loss of $699.8M against $38.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Sarepta Therapeutics Inc?
Sarepta Therapeutics Inc (SRPT) scores 44 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.